Characterisation of IgA Nephropathy in an Australian Cohort.

IF 1.7 Q3 UROLOGY & NEPHROLOGY
International Journal of Nephrology Pub Date : 2025-03-27 eCollection Date: 2025-01-01 DOI:10.1155/ijne/9976879
Shriram Swaminathan, Nithya Neelakantan, Henry Bryant, Pimvara Rattanamastip, Gagandeep Sandhu, Bobby Chacko
{"title":"Characterisation of IgA Nephropathy in an Australian Cohort.","authors":"Shriram Swaminathan, Nithya Neelakantan, Henry Bryant, Pimvara Rattanamastip, Gagandeep Sandhu, Bobby Chacko","doi":"10.1155/ijne/9976879","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> This retrospective cohort study aims to evaluate the prognostic factors for progression of immunoglobulin A nephropathy (IgAN) to kidney failure (defined as the initiation of kidney replacement therapy or death) and all-cause mortality in an Australian population. <b>Methods:</b> We conducted a retrospective analysis of 363 individual patients with biopsy-proven IgAN over a 21-year period (2000-2020) in the Hunter Region of New South Wales. Demographic data, comorbidities, biopsy features and biochemical markers were collected for a minimum of 12 months following biopsy diagnosis. A multivariable analysis using Cox regression was performed to examine their association with renal progression. <b>Results:</b> A total of 104 patients met the inclusion criteria and were followed for a median of 72 months. The cohort had a mean age at presentation of 45 years, with a predominantly male population. Most patients presented with haematuria and non-nephrotic range proteinuria. We stratified patients into three risk categories: low risk, intermediate risk, and high risk. Twenty-eight patients (26.92%) developed kidney failure and 15 patients (14.4%) experienced a > 20 mL/min eGFR decline within the first 12 months. The multivariable analysis revealed the following key factors associated with kidney failure: additional renal pathology on biopsy (HR 3.90, 95% CI 1.63-9.29), proteinuria (HR 1.15, 95% CI 1.02-1.29) and moderate-severe interstitial fibrosis/tubular atrophy (T2) (HR 7.00, 95% CI 2.32-21.05). There were 17 deaths (16.3%) in the cohort, with a mean survival time of 167.8 months (95% CI 152.6-183.1). <b>Conclusion:</b> In contrast to earlier reports from Australia, our findings emphasise that the progression to kidney failure is not uncommon in IgAN. We identified several predictors of the renal progression that are consistent with the previous studies. This highlights the need for a change in clinical management, as IgAN should no longer be considered a benign condition.</p>","PeriodicalId":14177,"journal":{"name":"International Journal of Nephrology","volume":"2025 ","pages":"9976879"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968155/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ijne/9976879","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: This retrospective cohort study aims to evaluate the prognostic factors for progression of immunoglobulin A nephropathy (IgAN) to kidney failure (defined as the initiation of kidney replacement therapy or death) and all-cause mortality in an Australian population. Methods: We conducted a retrospective analysis of 363 individual patients with biopsy-proven IgAN over a 21-year period (2000-2020) in the Hunter Region of New South Wales. Demographic data, comorbidities, biopsy features and biochemical markers were collected for a minimum of 12 months following biopsy diagnosis. A multivariable analysis using Cox regression was performed to examine their association with renal progression. Results: A total of 104 patients met the inclusion criteria and were followed for a median of 72 months. The cohort had a mean age at presentation of 45 years, with a predominantly male population. Most patients presented with haematuria and non-nephrotic range proteinuria. We stratified patients into three risk categories: low risk, intermediate risk, and high risk. Twenty-eight patients (26.92%) developed kidney failure and 15 patients (14.4%) experienced a > 20 mL/min eGFR decline within the first 12 months. The multivariable analysis revealed the following key factors associated with kidney failure: additional renal pathology on biopsy (HR 3.90, 95% CI 1.63-9.29), proteinuria (HR 1.15, 95% CI 1.02-1.29) and moderate-severe interstitial fibrosis/tubular atrophy (T2) (HR 7.00, 95% CI 2.32-21.05). There were 17 deaths (16.3%) in the cohort, with a mean survival time of 167.8 months (95% CI 152.6-183.1). Conclusion: In contrast to earlier reports from Australia, our findings emphasise that the progression to kidney failure is not uncommon in IgAN. We identified several predictors of the renal progression that are consistent with the previous studies. This highlights the need for a change in clinical management, as IgAN should no longer be considered a benign condition.

澳大利亚队列中IgA肾病的特征。
目的:这项回顾性队列研究旨在评估澳大利亚人群中免疫球蛋白A肾病(IgAN)进展至肾衰竭(定义为开始肾脏替代治疗或死亡)和全因死亡率的预后因素。研究方法我们对新南威尔士州猎人区 21 年间(2000-2020 年)活检证实的 363 例 IgAN 患者进行了回顾性分析。我们收集了活检确诊后至少 12 个月内的人口统计学数据、合并症、活检特征和生化指标。采用 Cox 回归方法进行了多变量分析,以研究这些因素与肾病进展的关系。结果共有 104 名患者符合纳入标准,随访时间中位数为 72 个月。患者发病时的平均年龄为 45 岁,以男性为主。大多数患者出现血尿和非肾病范围的蛋白尿。我们将患者分为三个风险类别:低风险、中风险和高风险。28名患者(26.92%)出现肾衰竭,15名患者(14.4%)在最初的12个月内eGFR下降> 20毫升/分钟。多变量分析显示了以下与肾衰竭相关的关键因素:活检发现其他肾脏病变(HR 3.90,95% CI 1.63-9.29)、蛋白尿(HR 1.15,95% CI 1.02-1.29)和中度-重度间质纤维化/肾小管萎缩(T2)(HR 7.00,95% CI 2.32-21.05)。队列中有 17 人死亡(16.3%),平均存活时间为 167.8 个月(95% CI 152.6-183.1)。结论与澳大利亚的早期报告相比,我们的研究结果强调,IgAN进展为肾衰竭的情况并不少见。我们发现了几种预测肾衰进展的因素,与之前的研究结果一致。这凸显了改变临床管理的必要性,因为 IgAN 不应再被视为良性疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Nephrology
International Journal of Nephrology UROLOGY & NEPHROLOGY-
CiteScore
3.40
自引率
4.80%
发文量
44
审稿时长
17 weeks
期刊介绍: International Journal of Nephrology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies focusing on the prevention, diagnosis, and management of kidney diseases and associated disorders. The journal welcomes submissions related to cell biology, developmental biology, genetics, immunology, pathology, pathophysiology of renal disease and progression, clinical nephrology, dialysis, and transplantation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信